论文部分内容阅读
随机抽取2013年9月~2014年9月于我院接受治疗的100例功能性消化不良患者作为研究对象,按照随机数字表法将分为对照组与观察组各50例。对照组接受埃索美拉唑联合多潘立酮方案治疗,观察组则接受奥美拉唑联合曲美布汀方案治疗,比较两组患者临床症状的改善情况,统计两组患者的临床治疗效果。结果治疗后,观察组腹痛、胃部灼烧感、嗳气、腹胀症状积分分别下降至(0.96±0.15)、(0.75±0.24)、(1.16±0.13)、(2.34±0.16)分,均明显低于对照组(P<0.05);观察组显效21例,有效26例,临床治疗总有效率高达94.00%,明显高于对照组的76.00%,组间对比差异有统计学意义(P<0.05)。在功能性消化不良患者的临床治疗中,可采用奥美拉唑联合曲美布汀方案,以优化临床治疗效果,改善患者的临床症状,缩短患者的康复时间,提高治疗的安全性。
A total of 100 patients with functional dyspepsia treated in our hospital from September 2013 to September 2014 were randomly selected as study subjects and divided into control group and observation group according to random number table method. The control group received esopramzole combined with domperidone regimen, while the observation group received omeprazole combined with trimebutine regimen. The improvement of clinical symptoms was compared between the two groups, and the clinical effect of both groups was statistically evaluated. Results After treatment, the scores of abdominal pain, burning sensation of stomach, belching and abdominal distension decreased to (0.96 ± 0.15), (0.75 ± 0.24), (1.16 ± 0.13) and (2.34 ± 0.16) points in observation group (P <0.05). The observation group was effective in 21 cases and effective in 26 cases. The total effective rate in clinical treatment was 94.00%, significantly higher than that in the control group (76.00%). The difference between the two groups was statistically significant (P <0.05) . In patients with functional dyspepsia clinical treatment, omeprazole trimebutine combination regimen can be used to optimize clinical treatment, improve clinical symptoms, shorten the recovery time of patients and improve the safety of treatment.